Report : South America Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology (Molecular Diagnostics {Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, Microarrays}, Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology), Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)
At 8.8% CAGR, the South America Sepsis Diagnostics Market is speculated to be worth US$ 69.59 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the SAM sepsis diagnostics market was valued at US$ 38.66 million in 2021 and is expected to reach US$ 69.59 million by 2028, registering an annual growth rate of 8.8% from 2021 to 2028. High incidence of sepsis due to increasing nosocomial infections and rise in demand for rapid diagnostic tests leading to increasing product launches are the critical factors attributed to the market expansion.
The rising need for rapid diagnostics for sepsis fueled the research activities among key players in recent years. Both the existing players and the start-ups in sepsis diagnostics are well supported financially by government and research organizations. For instance, in April 2020, Cytovale Inc. announced its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for sepsis diagnosis in patients with respiratory infections, including COVID-19. The research was estimated to stand at US$ 5.9 million, with a contribution of approximately US$ 3.83 million by BARDA. Additionally, in an endeavor to shape the future of sepsis research, National Institute of General Medical Sciences (NIGMS) intends to use the NIH SBIR/STTR program to support preclinical and clinical sepsis studies to develop improved diagnostic tools and therapies. Diagnostics companies are continuously securing funding to establish rapid sepsis diagnostic tests. For instance, in June 2021, HelixBind secured a US$ 3 million grant from the National Institutes of Health (NIH) to support the testing of its rapid diagnostic platform for invasive infections associated with sepsis. The financial support aided the research and led to the evolution of novel biomarkers for sepsis diagnosis. Biomarkers offer a tool for facilitating early diagnosis, identifying patient populations at high risk of complications, and monitoring the disease's progression, which are critical assessments for appropriate therapy and improvement in patient outcomes. Also, the launch of effective treatments and ongoing clinical trials will provide beneficial opportunities for the sepsis diagnostics market during the forecast period. This is expected to drive the market during the forecast period.
On the contrary, lack of skilled professionals hurdles the growth of SAM sepsis diagnostics market.
Based on product, the SAM sepsis diagnostics market is divided into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held 44.4% market share in 2021, amassing US$ 17.18 million. It is projected to garner US$ 30.69 million by 2028 to expand at 8.6% CAGR during 2021–2028.
Based on technology, the SAM sepsis diagnostics market is categorized into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held 45.0% market share in 2021, amassing US$ 17.40 million. It is projected to garner US$ 30.82 million by 2028 to expand at 8.5% CAGR during 2021–2028. Further molecular diagnostics flow cytometry segment is further categorized into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, microarrays
Based on Method, the SAM sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held 67.1% market share in 2021, amassing US$ 25.94 million. It is projected to garner US$ 46.23 million by 2028 to expand at 8.6% CAGR during 2021–2028
Based on test type, the SAM sepsis diagnostics market is divided into point-of-care tests and laboratory tests. The laboratory tests segment held 84.7% market share in 2021, amassing US$ 32.73 million. It is projected to garner US$ 58.68 million by 2028 to expand at 8.7% CAGR during 2021–2028
Based on pathogen, the SAM sepsis diagnostics market is divided into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held 79.8% market share in 2021, amassing US$ 30.86 million. It is projected to garner US$ 56.36 million by 2028 to expand at 9.0% CAGR during 2021–2028
Based on end user, the SAM sepsis diagnostics market is divided into hospitals, pathology and reference laboratories, and others. The hospitals segment held 48.0% market share in 2021, amassing US$ 18.54 million. It is projected to garner US$ 33.63 million by 2028 to expand at 8.9% CAGR during 2021–2028
Based on country, the SAM sepsis diagnostics market has been categorised into the Brazil, Argentina, and Rest of SAM. Our regional analysis states that Brazil captured 43.1% market share in 2021. It was assessed at US$ 16.67 million in 2021 and is likely to hit US$ 30.67 million by 2028, exhibiting a CAGR of 9.1% during the forecast period.
Key players dominating the SAM sepsis diagnostics market are Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; and T2 Biosystems, Inc. among others.
- In April 2022, bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics.
- In Nov 2021, T2 Biosystems Announces Continued International Expansion with Exclusive Distribution Agreement.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com